Franklin Resources Inc. Has $47.55 Million Stock Position in Repligen Co. (NASDAQ:RGEN)

Franklin Resources Inc. boosted its holdings in shares of Repligen Co. (NASDAQ:RGEN) by 8.7% in the third quarter, Holdings Channel.com reports. The fund owned 332,405 shares of the biotechnology company’s stock after buying an additional 26,668 shares during the quarter. Franklin Resources Inc.’s holdings in Repligen were worth $47,551,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Andra AP fonden bought a new stake in shares of Repligen in the second quarter worth about $25,000. UMB Bank n.a. raised its position in Repligen by 138.3% in the 3rd quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company’s stock valued at $33,000 after buying an additional 130 shares during the last quarter. Blue Trust Inc. lifted its position in shares of Repligen by 113.4% in the third quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 127 shares in the last quarter. Resources Management Corp CT ADV bought a new stake in Repligen during the 3rd quarter worth about $37,000. Finally, International Assets Investment Management LLC acquired a new position in shares of Repligen during the 2nd quarter worth about $33,000. Institutional investors own 97.64% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently weighed in on RGEN. Wolfe Research began coverage on shares of Repligen in a research note on Thursday, November 14th. They issued a “peer perform” rating for the company. Canaccord Genuity Group began coverage on shares of Repligen in a research note on Tuesday. They set a “hold” rating and a $165.00 target price for the company. Wells Fargo & Company assumed coverage on Repligen in a research report on Tuesday, August 27th. They issued an “overweight” rating and a $180.00 target price on the stock. StockNews.com upgraded shares of Repligen from a “sell” rating to a “hold” rating in a research note on Friday, November 22nd. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $205.00 target price on shares of Repligen in a report on Thursday, September 26th. Six equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $185.20.

Repligen Stock Performance

NASDAQ:RGEN opened at $158.14 on Wednesday. The firm has a market capitalization of $8.86 billion, a PE ratio of -427.41, a price-to-earnings-growth ratio of 4.64 and a beta of 0.96. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. The stock’s 50-day simple moving average is $143.15 and its 200 day simple moving average is $141.68. Repligen Co. has a twelve month low of $113.50 and a twelve month high of $211.13.

Repligen (NASDAQ:RGEN) last posted its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 EPS for the quarter, beating the consensus estimate of $0.34 by $0.09. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. The firm had revenue of $154.87 million during the quarter, compared to the consensus estimate of $153.34 million. During the same period last year, the company earned $0.23 earnings per share. The business’s quarterly revenue was up 9.7% on a year-over-year basis. On average, analysts anticipate that Repligen Co. will post 1.54 EPS for the current fiscal year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.